The following materials are available for your practice. Make sure to bookmark this page as these materials may be updated periodically. Many of the materials are provided in Adobe Acrobat PDF format. If you don't have Acrobat Reader, you can download it below.
Ethnic Patient Materials: Coming Soon
Use these Ethnic Patient Materials with your appropriate osteoporosis patients.
Physicians' Reference Tool: Coming Soon
The Physicians' Reference Tool gives you valuable information about osteoporosis and fractures, including statistics, risk factors, images of normal and osteoporotic bone, and a comparison of available osteoporosis treatment options—all in a helpful, interactive format.
Information Regarding Osteonecrosis of the Jaw
Read a statement by The Alliance for Better Bone Health regarding Actonel and reported cases of osteonecrosis of the jaw.
Click here to download the statement.
Free Trial Offer for Your Patients
Help your patients get started on Actonel 150 mg Once-a-Month with a one-month supply of Actonel.
Print out this Free Trial Voucher and give it to your appropriate patients with their Actonel prescription. Your patients can then redeem their Free One-Month Trial Voucher at their pharmacy when they fill their prescription for Actonel.
Click here to download the Free Trial Voucher.
Actonel Monthly Reminders
Help your patients stay on treatment with monthly reminders. Tell your patients to call 1-800-324-4040 or have them visit Actonel.com/reminders to sign up.
Patient Education Brochure
Use this brochure to help your patients better understand osteoporosis and the importance of maintaining their bone strength.
Click here to download the Patient Education Brochure.
Actonel Patient Support Brochure
Help your patients get extra support, including information about how to save on their Actonel prescription.
Click here to download the Actonel Patient Support Brochure.
Actonel is indicated for the treatment of postmenopausal osteoporosis.
Actonel 5 mg and 35 mg are indicated for the prevention of postmenopausal osteoporosis.
Actonel 150 mg may be considered for use for prevention of postmenopausal osteoporosis.
Selected Safety Information for Actonel
Actonel is contraindicated in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least
30 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).
Bisphosphonates, including Actonel, may cause upper gastrointestinal disorders such as dysphagia, esophagitis and esophageal or gastric ulcers. Actonel should be taken according to the dosing instructions to minimize the risk of these events. Patients should discontinue use if new or worsening symptoms occur. There have also been reports of severe and occasionally incapacitating bone, joint and/or muscle pain in patients taking bisphosphonates.
Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including Actonel. Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Clinical judgment of the treating physician and/or oral surgeon should guide the management plan (including the consideration of discontinuation of bisphosphonate therapy) of each patient based on individual benefit/risk assessment.
Most common adverse reactions reported in >10% of patients treated with Actonel and with a higher frequency than placebo are: back pain, arthralgia, abdominal pain, and dyspepsia. Hypersensitivity reactions (angioedema, generalized rash, bullous skin reactions), and eye inflammation (iritis, uveitis) have been reported rarely.
Please click for Full Prescribing Information for Actonel.
This material is provided in Adobe Acrobat PDF format. If you don't have Acrobat Reader, you can download it by clicking below.
